USO 22284

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective Study (MYLUNG Consortium: Part 3) Module A: Project ENGAGE: Increasing Biomarker Testing Awareness in Patients with Non-Small-Cell Lung Cancer Through Patient Education

Disease Types: Lung Cancer Research

Eligibility Requirements:

- Written informed consent, according to local guidelines, signed and dated by the participant or by a legal guardian prior to the performance of any study-specific procedures, sampling, or analyses

- Adult participants (18 years and older at the time of signature of the Informed Consent Form [ICF]) with early-stage, locally advanced, or metastatic NSCLC

- Must be eligible for systemic therapy based on the treating provider assessment. If systemic therapy was recommended and documented by the treating provider but the participant declined, they can still be eligible for the study

- Participants who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy (including chemoradiation) are eligible if the therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease.

- Participants with early-stage, locally advanced, and metastatic disease must be enrolled prior to start of first systemic treatment. For participants previously given neoadjuvant/adjuvant treatment, please refer to Inclusion #4.

- Must be able to read and answer survey questions in English or Spanish

- Agree to participate in the LUNGevity Biomarker Participant Survey and Registry

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg